test

Developmental Therapeutics

Howard S Hochster MD

Professor of Medicine (Medical Oncology); Associate Director for Clinical Sciences, Yale Cancer Center; Clinical Program Leader, Gastrointestinal Cancers Program, Smilow Cancer Hospital; Clinical Research Program Leader, Gastrointestinal Cancers Program, Yale Cancer Center

Clinical Interests

gastrointestinal cancer; colon cancer; pancreatic cancer; gastric cancer; biliary cancer


Board Certifications

1986
Hematology (Internal Medicine), Board Certified
1983
Internal Medicine, Board Certified
Medical Oncology, Board Certified

Patient Care Locations

howard_hochsterfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Colorectal Cancer and ColonA Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (CALGB 80702)
PancreasPhase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, and StomachA Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
ColonS0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

More Clinical Trials...

Edit Profile